Protocol Ledger

NCT06981637 · Phase II · RECRUITING

Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

Interventional Phase II clinical trial protocol NCT06981637 sponsored by National Health Research Institutes, Taiwan in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-31 Enrollment: 81 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06981637
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)81 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06981637
Protocol FieldVerified Registry Value
NCT IdentifierNCT06981637
Consolidated Lead SponsorNational Health Research Institutes, Taiwan
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment81 participants (ESTIMATED)
Registered Start Date2025-12-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI